Skip to main navigation

Skip to Content

Menu

About Cerevel
Our Programs
- Tavapadon
- CVL-871
- CVL-865
- CVL-231
- CVL-936
Our Science
- Our scientific strategy
- Our pipeline
Investor & Media
Careers
- Working at Cerevel Therapeutics
- Open positions
Contact Us

News & Announcements

News & Announcements

Year

Jul 22, 2021

Cerevel Therapeutics to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021

Jul 01, 2021

Cerevel Therapeutics Announces Pricing of $350 Million Public Offering of Common Stock

Jun 29, 2021

Cerevel Therapeutics Announces Proposed Public Offering of Common Stock

Jun 29, 2021

Cerevel Therapeutics Announces Positive Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schizophrenia

Jun 15, 2021

Cerevel Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to CVL-871 for the Treatment of Dementia-Related Apathy

May 27, 2021

Cerevel Therapeutics to Present at Upcoming Virtual Investor Conferences

May 17, 2021

Cerevel Therapeutics Reports First Quarter 2021 Financial Results and Business Updates

May 04, 2021

Cerevel Therapeutics Announces the Appointment of Scott M. Akamine as Chief Legal Officer

Apr 29, 2021

Cerevel Therapeutics to Report First Quarter 2021 Financial Results on Monday, May 17, 2021

Apr 21, 2021

Cerevel Therapeutics Appoints Abraham N. Ceesay as President

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 17

Print

RSS Feeds

Email Alerts

Investor Contact

Search

Cerevel

About CerevelAbout Cerevel
Our ProgramsOur Programs
- Tavapadon
- CVL-871
- CVL-865
- CVL-231
- CVL-936
Our ScienceOur Science
- Our scientific strategy
- Our pipeline
NewsroomNewsroom
CareersCareers
- Working at Cerevel Therapeutics
- Open Positions
Contact Us

Facebook
Twitter
LinkedIn
YouTube

Cerevel

Terms of Use
Privacy Policy

© 2021 Cerevel Therapeutics

CEREVEL and the CEREVEL logo are trademarks of

Cerevel Therapeutics. All Rights Reserved.